Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation

2005 ◽  
Vol 12 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Roberto J. Firpi ◽  
Haizhen Zhu ◽  
Giuseppe Morelli ◽  
Manal F. Abdelmalek ◽  
Consuelo Soldevila-Pico ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Virological Response

scholarly journals PEGYLATED INTERFERON AND RIBAVIRIN FOR TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: a single-liver transplant center experience in Brazil

2015 ◽  
Vol 52 (3) ◽  
pp. 216-221
Author(s):  
José Huygens Parente GARCIA ◽  
Antônio Haroldo de ARAÚJO FILHO ◽  
Lucia Libanez Bessa Campelo BRAGA ◽  
Cyntia Ferreira Gomes VIANA ◽  
Tarciso Daniel Santos ROCHA ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Sustained Virological Response ◽  
Virological Response ◽  
Response Rate ◽  
Pegylated Interferon ◽  
Antiviral Drugs ◽  
Recipient Age

BackgroundTreatment of hepatitis C virus infection in post-transplantation patients is a challenge due to poor tolerance and low success rates.ObjectiveTo determine the response rate to pegylated interferon and ribavirin in post-liver transplant patients with hepatitis C recurrence.MethodsBetween 18 May 2002 and 18 December 2011, 601 patients underwent liver transplantation at our service (Hospital Universitário Walter Cantídio, University of Ceará), 176 (29.2%) of whom were hepatitis C virus positive. Forty received antiviral therapy and were included in this cohort study. Twenty-eight (70%) completed the treatment protocol, which consisted of pegylated interferon and ribavirin for 48 weeks.ResultsThe sustained virological response rate was 55% according to intention-to-treat analysis. Recipient age and exposure to antiviral drugs prior to liver transplantation were associated with sustained virological response in the multivariate analysis. Patients were followed for 57 months on the average. Survival at 1 and 5 years was 100% in responders, versus 100% and 78%, respectively, in non-responders.ConclusionSustained virological response rates were satisfactory in our series of liver transplantation patients, and decreased with increasing recipient age. Non-exposure to antiviral drugs prior to liver transplantation was positively associated with sustained virological response. The overall survival of responders and non-responders was similar.

scholarly journals Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection

Viruses ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 531 ◽  
Author(s):  
C. Hayes ◽  
Peiyi Zhang ◽  
Yizhou Zhang ◽  
Kazuaki Chayama
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Molecular Mechanisms ◽  
Significant Difference ◽  
Chronic Hepatitis C Virus

Despite the success of direct-acting antiviral (DAA) agents in treating chronic hepatitis C virus (HCV) infection, the number of cases of HCV-related hepatocellular carcinoma (HCC) is expected to increase over the next five years. HCC develops over the span of decades and is closely associated with fibrosis stage. HCV both directly and indirectly establishes a pro-inflammatory environment favorable for viral replication. Repeated cycles of cell death and regeneration lead to genomic instability and loss of cell cycle control. DAA therapy offers >90% sustained virological response (SVR) rates with fewer side effects and restrictions than interferon. While elimination of HCV helps to restore liver function and reverse mild fibrosis, post-SVR patients remain at elevated risk of HCC. A series of studies reporting higher than expected rates of HCC development among DAA-treated patients ignited debate over whether use of DAAs elevates HCC risk compared to interferon. However, recent prospective and retrospective studies based on larger patient cohorts have found no significant difference in risk between DAA and interferon therapy once other factors are taken into account. Although many mechanisms and pathways involved in hepatocarcinogenesis have been elucidated, our understanding of drivers specific to post-SVR hepatocarcinogenesis is still limited, and lack of suitable in vivo and in vitro experimental systems has hampered efforts to examine etiology-specific mechanisms that might serve to answer this question more thoroughly. Further research is needed to identify risk factors and biomarkers for post-SVR HCC and to develop targeted therapies based on more complete understanding of the molecules and pathways implicated in hepatocarcinogenesis.

scholarly journals Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro

Hepatology ◽  
2008 ◽  
Vol 49 (5) ◽  
pp. 1431-1441 ◽  
Author(s):  
Sonya A. MacParland ◽  
Tram N. Q. Pham ◽  
Clifford S. Guy ◽  
Tomasz I. Michalak
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Sustained Virological Response ◽  
Virological Response

scholarly journals A case of hepatitis B virus and hepatitis C virus co-infection that achieved sustained virological response 12 following treatment with glecaprevir hydrate/pibrentasvir for 3 days

Kanzo ◽  
2021 ◽  
Vol 62 (9) ◽  
pp. 578-584
Author(s):  
Yasunao Numata ◽  
Shigeru Sasaki ◽  
Noriyuki Akutsu ◽  
Takehiro Hirano ◽  
Kohei Wagatsuma ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Sustained Virological Response ◽  
Virological Response ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document